

Results of Clinical Trial PA.6 Announced in Chicago

On June 4, 2018 at the American Society of Clinical Oncology in Chicago, the results of the clinical trial called PRODIGE 24/CCTG PA.6 were announced, marking an important advancement in pancreatic cancer treatment and the standard of care.

The trial, which was sponsored by the CCTG (Canadian Cancer Trials Group) in Canada and UNICANCER in France, showed that patients with surgically removed pancreatic cancer who received a four-drug combo chemotherapy called mFOLFIRINOX, lived an average of 20 months longer than those who received the current standard of post-surgery chemo, gemcitabine.

The surgery that precedes this combination therapy is still only possible for 10-20% of people diagnosed with pancreatic cancer. While this form of treatment isn't for the masses, it is still an important development in advancing new treatment options for patients and in most cases leads longer survival.

"The results of this trial are striking. Patients treated with the newer so-called Folfirinox regimen were twice as likely to remain free of their disease 3 years later. We have to wait a bit longer for the trial results to mature before we can confirm how this translates to increased cure rates," said Dr. Jim Biagi, PancOne™ investigator and PA.6 Canadian study co-chair.

"Despite the importance of this trial, its results help only a proportion of patients who are diagnosed with pancreatic cancer (10-20%). We still need to better understand the disease and thus are thrilled that the PancOne™ collaboration through Pancreatic Cancer Canada is up and running to delve into the underlying mechanisms of pancreatic cancer."

We are excited and motivated by this announcement as we continue our commitment to innovative research through PancOne™ to better understand and treat pancreatic cancer in all patients.

Source: American Society of Clinical Oncology in Chicago, ["Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer"](#)

News Coverage: Global News, ["Four-drug combo can help pancreatic patients live 'substantially' longer: study"](#)